Definium Therapeutics Announces FDA Breakthrough Designation for DT120 ODT

What Happened
Definium Therapeutics, Inc. (DFTX) filed an 8-K on September 8, 2026 to announce that the U.S. Food and Drug Administration granted Breakthrough Therapy designation to the company’s DT120 ODT program for the treatment of major depressive disorder. The company issued a press release on the same date; that press release is attached to the 8‑K as Exhibit 99.1.

Key Details

• Filing date: September 8, 2026 (Form 8-K, Item 8.01 – Other Events).
• Program: DT120 ODT (oral dissolving tablet) for major depressive disorder.
• Regulatory update: FDA granted Breakthrough Therapy designation for DT120 ODT.
• Exhibit: Press release dated September 8, 2026 filed as Exhibit 99.1 to the 8‑K; filing signed by CEO Robert Barrow.

Why It Matters
Breakthrough Therapy designation is an FDA pathway intended to expedite the development and review of drugs for serious conditions when preliminary clinical evidence indicates substantial improvement over existing therapies. For investors, this designation may lead to increased regulatory interaction and could potentially accelerate DT120’s clinical and review timeline, raising program visibility and strategic value for Definium’s pipeline. The 8‑K documents the regulatory milestone but does not provide new clinical data or timing details.